RARITAN, N.J., March 9, 2020 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory solutions, ...
Raritan-based Ortho Clinical Diagnostics said April 3, it is launching to market its COVID-19 antibody test. The VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack testing kits are ...
- Ortho's new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2 Antibody assay receive CE Mark - Both tests can aid in identifying individuals with an adaptive immune ...
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, has received approval from the U.S. Food and Drug Administration (FDA) for Ortho's VITROS ® Immunodiagnostic Products HBeAg ...
RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...
RARITAN, N.J., April 16, 2019 /PRNewswire/ -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced CE Mark for its next-generation VITROS® High Sensitivity Troponin I assay.
Vitros iPTH assay streamlines protocol for both routine and intraoperative testing. Ortho-Clinical Diagnostics received FDA 510(k) clearance for its Vitros intact Parathyroid Hormone (iPTH) Assay. The ...
The FDA approved Ortho Clinical Diagnostics’ Vitros fourth-generation HIV combination test, which detects both HIV-1 and HIV-2 antibodies and the p24 antigen, which the company says allows it to ...
March 17, 2006 — The US Food and Drug Administration (FDA) has approved a 3-dimensional mapping system to identify cardiac tissue that could benefit from targeted investigational therapies; an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results